<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Tuesday, Feb 19th, 2019
DoubleTree by Hilton – Mission Valley, San Diego, CA

Translation of multiplex proteomics assays from discovery to the clinical laboratory

The following topics will be discussed:

  • Developing diagnostics for blood
  • Biomarker panel selection
  • Key advantages of LC-MS/MS
  • Data analytics and Informatics
  • Clinical assay development and validatin
  • Other possible topics include specific examples of LC-MS/MS applications
Steve Hunsucker

Speaker: Steve Hunsucker, Ph.D. Vice President of Laboratory Operations, Seattle at Biodesix

Dr. Hunsucker has studied and applied a wide variety of mass spectrometry and proteomics approaches over the past twenty-five years. He was a key member of the team responsible for discovery and validation of the first protein-targeted MRM MS assay to reach the clinic, Xpresys™ Lung. The assay aims to help physicians identify benign pulmonary nodules with high probability, in an effort to help eliminate unnecessary invasive procedures associated with the diagnosis of pulmonary nodules.

Earlier in his career, Dr. Hunsucker was part of the Biodesix team responsible for commercialization of a MALDI MS assay, now known as Veristrat®. He was primarily responsible for establishing a clinical-grade assay in a CLIA-certified mass spectrometry laboratory. Prior to that, Dr. Hunsucker was part of an international collaboration that published the discovery and validation of the Veristrat assay, which measured serum proteins to classify non-small-cell lung cancer patients into two groups based on clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors.